Merrimack Pharmaceuticals (MACK)
14.26
-0.64 -4.30%
NASDAQ
Sep 22, 20:00
Delayed 2m
USD
View All Key Stats
MACK Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | 31.50 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | 419.36M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -- |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0.00 |
| Price and Valuation | |
| Market Cap | 189.37M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | -- |
| PE Ratio (TTM) | 0.4527 |
| Price to Book Value | 1.778 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | -- |
| Free Cash Flow (Quarterly) | -85.35M |
| Return on Equity (TTM) | -- |
View All MACK News
MACK News
-
WireHeadlineTime (ET)
-
Yahoo09/20 16:15
-
Yahoo09/07 08:00
-
Yahoo08/31 09:39
-
SA Breaking News08/31 09:11
-
MT Newswires08/31 08:42
-
PR Newswire08/31 08:00
-
PR Newswire08/23 06:50
-
SA Breaking News08/14 11:29
-
MT Newswires08/14 07:24
-
PR Newswire08/14 06:55
View All Events
MACK Events
| Date | Type | Description |
|---|---|---|
| 09/06/2017 | Splits | Ratio: 1:10 |
| 08/11/2017 | Misc | Merrimack Pharmaceuticals Inc Annual General Meeting in 2016 |
| 05/30/2017 | Dividends | Amount: 10.60, Declared Date: Apr 05 2017, Pay Date: May 26 2017 |
| 05/10/2017 | Earnings | Merrimack Pharmaceuticals Inc First Quarter Earnings in 2017 Release |
| 05/10/2017 | Misc | Merrimack Pharmaceuticals Inc First Quarter Earnings Conference Call in 2017 |
| 03/01/2017 08:30 EST | Misc | Merrimack Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2016 |
| 03/01/2017 | Earnings | Merrimack Pharmaceuticals Inc Fourth Quarter Earnings in 2016 Release |
| 11/09/2016 16:30 EDT | Misc | Merrimack Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2016 |
| 11/09/2016 | Earnings | Merrimack Pharmaceuticals Inc Third Quarter Earnings in 2016 Release |
MACK Fundamentals
Income Statement View Statement
MACK Ratings
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
Advertisement
MACK One Page Reports
- One Page Report Download
MACK Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Target Price | |
| Price | 14.26 |
| Price Target | Upgrade |
Edit
Profile
- URL: http://www.merrimack.com
- Investor Relations URL: http://investors.merrimackpharma.com/
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Biotechnology
- Next Earnings Release: N/A
- Last Earnings Release: May. 10, 2017
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: May. 30, 2017
- Description: Merrimack Pharmaceuticals Inc is a biotechnology company. It discovers, develops, and commercializes innovative medicines consisting of novel therapeutics paired with diagnostics to treat various types of cancer.
MACK Comparables
EditMACK Excel Add-In Codes
- Name: =YCI("MACK","name")
- Description: =YCI("MACK","description")
- Sector: =YCI("MACK","sector")
- Industry: =YCI("MACK","industry")
- Est. Current Fiscal Year End: =YCI("MACK","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Other MACK Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- MACK Tweets Stocktwits
Advertisement
